Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 31, 2022

Study Completion Date

December 31, 2023

Conditions
Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults
Interventions
BIOLOGICAL

Individual peptide vaccination with adjuvant GM-CSF and Imiquimod

Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.

Trial Locations (5)

13353

Charite Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology, Berlin

40225

University Hospital Düsseldorf, Clinic for Pediatric Oncology, Hematology and Clinical Immunology, Düsseldorf

69120

University Medical Center for Children and Adolescents Heidelberg, Heidelberg

72076

University Children's Hospital Tübingen, Tübingen

80337

University Children's Hospital Munich, Center for Pediatric Hematology and Oncology, München

All Listed Sponsors
collaborator

German Cancer Research Center

OTHER

collaborator

Universität Tübingen

OTHER

collaborator

University Hospital Tuebingen

OTHER

lead

University Children's Hospital Tuebingen

OTHER

NCT03559413 - Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL | Biotech Hunter | Biotech Hunter